Incyte (NASDAQ:INCY) Insider Thomas Tray Sells 600 Shares of Stock

Incyte Corporation (NASDAQ:INCY) insider Thomas Tray sold 600 shares of Incyte stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $98.25, for a total value of $58,950.00. Following the completion of the transaction, the insider directly owned 22,973 shares in the company, valued at approximately $2,257,097.25. This represents a 2.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Thomas Tray also recently made the following trade(s):

• On Friday, December 19th, Thomas Tray sold 2,774 shares of Incyte stock. The stock was sold at an average price of $100.00, for a total transaction of $277,400.00.

Incyte Stock Performance

Shares of Incyte stock opened at $100.71 on Tuesday. The business has a 50-day moving average price of $98.53 and a two-hundred day moving average price of $85.09. Incyte Corporation has a 1-year low of $53.56 and a 1-year high of $109.28. The company has a market cap of $19.77 billion, a P/E ratio of 16.87, a PEG ratio of 0.70 and a beta of 0.81. The company has a current ratio of 3.20, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.26 billion. During the same period in the prior year, the business earned $1.07 EPS. The company’s revenue for the quarter was up 20.0% compared to the same quarter last year. As a group, analysts anticipate that Incyte Corporation will post 4.86 EPS for the current year.

Institutional Trading of Incyte

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC grew its position in Incyte by 92.3% during the first quarter. AQR Capital Management LLC now owns 6,736,169 shares of the biopharmaceutical company’s stock valued at $405,787,000 after buying an additional 3,233,356 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Incyte by 701.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock worth $185,957,000 after buying an additional 2,390,084 shares in the last quarter. Norges Bank bought a new position in Incyte in the 2nd quarter valued at $96,776,000. Pacer Advisors Inc. grew its position in Incyte by 8,091.6% during the third quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock worth $105,897,000 after buying an additional 1,233,399 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Incyte in the 2nd quarter worth approximately $82,485,000. 96.97% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Japan regulatory wins expand commercial footprint — Japan approved Zynyz (retifanlimab) for first‑line advanced anal cancer and approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma. These approvals support additional revenue and market expansion in a major market. Article Title Article Title
• Neutral Sentiment: Momentum/analyst note: a Zacks piece flagged a recent ~5.5% rally and above‑average volume but warned that recent estimate revisions may limit near‑term upside — supportive of interest but not a clear buy signal on its own. Article Title
• Negative Sentiment: Insider selling: EVP and other insiders reported large sales — Incyte EVP sold about $5.25M of stock, and director/officer Thomas Tray disclosed sales totaling 3,374 shares across Dec. 18–19 (~$98–$100 per share). Large, concentrated insider sales can signal near‑term selling pressure or raise governance questions. Article Title SEC Filing

Analyst Upgrades and Downgrades

A number of brokerages recently commented on INCY. Barclays boosted their target price on Incyte from $101.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Truist Financial reiterated a “hold” rating and issued a $93.00 target price (up from $79.00) on shares of Incyte in a report on Wednesday, October 29th. JPMorgan Chase & Co. boosted their price target on shares of Incyte from $73.00 to $89.00 and gave the company a “neutral” rating in a research note on Thursday, October 9th. Mizuho set a $121.00 price objective on shares of Incyte and gave the stock an “outperform” rating in a report on Monday, December 8th. Finally, Royal Bank Of Canada lifted their price objective on shares of Incyte from $81.00 to $84.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Incyte presently has a consensus rating of “Hold” and a consensus target price of $99.07.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.